Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This is an investigator initiated, open label, prospective, non-randomized, phase II trial
aimed at evaluating the activity of Axitinib in progressive VEGFR2 and/or PDGFRB positive
advanced Solitary Fibrous Tumor (SFT) patients. Patients with a documented and centrally
reviewed pathologic and radiologic diagnosis of progressive VEGFR2 and/or PDGFRB positive
advanced SFT may enter in the study. Axitinib will be administered at the dose of 5mg twice a
day, continuously. Treatment will be continued till evidence of progression, or toxicities or
patient withdrawal.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano